Advances in the management of PML: Focus on natalizumab

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cleveland Clinic journal of medicine

• Publication date

  2011-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3949/ccjm.78.s2.08PMID 22123933
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Natalizumab-associated progressive multifocal leukoencephalopathy.

  2012cited by this paper
• Anti‐JC virus antibodies: Implications for PML Risk Stratification

  2010cited by this paper
• JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab

  2010cited by this paper
• Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

  2009cited by this paper
• Progressive Multifocal Leukencephalopathy in Patients on Highly Active Antiretroviral Therapy: Survival and Risk Factors of Death

  2004cited by this paper
• Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy.

  2003cited by this paper

• Immune Reconstitution Inflammatory Syndrome and Paradoxical Reaction

  2020cites this paper
• Immunomodulatory Therapy for Multiple Sclerosis

  2017cites this paper
• Introduction to Special Issue: Clinical Applications of Therapeutic Apheresis: An Evidence Based Approach. 7th Edition

  2016cites this paper
• Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue

  2016cites this paper
• Bench to Bedside and Beyond

  2016cites this paper
• Diagnostyka i leczenie postępującej wieloogniskowej leukoencefalopatii

  2015cites this paper
• Immune Reconstitution Inflammatory Syndrome Associated with Biologic Therapy

  2015cites this paper
• JC polyomavirus mutants escape antibody-mediated neutralization

  2015cites this paper
• Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.

  2015cites this paper
• Neurologic indications for therapeutic plasma exchange: 2013 update

  2014influential citation
• TREK-King the Blood–Brain-Barrier

  2014cites this paper
• Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango

  2014cites this paper
• Leucoencefalopatía multifocal progresiva asociada al uso de Natalizumab en un paciente con esclerosis múltiple. Primer caso en Latinoamérica. Hospital de San José - Bogotá 2013

  2014cites this paper
• Rapidly progressive cerebellar ataxia in West Wales

  2013cites this paper
• Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.

  2013cites this paper
• Central Nervous System Infections

  2013cites this paper
• Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue

  2013cites this paper
• Infratentorielle Progressive Multifokale Leukenzephalopathie

  2013cites this paper
• Infratentorielle Progressive Multifokale Leukenze- phalopathie Infratentorial Progressive Multifocal Leukoencephalopathy

  2013cites this paper
• MOLECULAR BASIS OF THE DEMYELINATING DISEASES

  2013cites this paper
• Natalizumab: bench to bedside and beyond.

  2013cites this paper
• Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice.

  2013cites this paper
• Natalizumab-associated complication? First case of peripheral T cell lymphoma

  2012cites this paper
• Leucoencefalopatia Multifocal Progressiva associada ao tratamento de Esclerose Múltipla com Natalizumab. A propósito de um caso clínico no Hospital Pêro da Covilhã.

  2012cites this paper
• Neurologic indications for therapeutic plasma exchange: 2011 update

  2012influential citation
• Complications of Immunosuppressive/Immunomodulatory Therapy in Neurological Diseases

  2012cites this paper
• Erratum: Special issue: Clinical applications of therapeutic apheresis: An evidence based approach. 5th edition

  2010cites this paper